EP3778569A4 - Inhibiteur d'assemblage de protéines capsidiques contenant un cycle à cinq chaînons n-hétérocyclique, composition pharmaceutique et utilisation associées - Google Patents
Inhibiteur d'assemblage de protéines capsidiques contenant un cycle à cinq chaînons n-hétérocyclique, composition pharmaceutique et utilisation associées Download PDFInfo
- Publication number
- EP3778569A4 EP3778569A4 EP19777163.7A EP19777163A EP3778569A4 EP 3778569 A4 EP3778569 A4 EP 3778569A4 EP 19777163 A EP19777163 A EP 19777163A EP 3778569 A4 EP3778569 A4 EP 3778569A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- heterocyclic
- pharmaceutical composition
- membered ring
- capsid protein
- protein assembly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000565 Capsid Proteins Proteins 0.000 title 1
- 102100023321 Ceruloplasmin Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810286111 | 2018-03-30 | ||
| CN201810730325 | 2018-07-05 | ||
| CN201910073465 | 2019-01-25 | ||
| PCT/CN2019/080412 WO2019185016A1 (fr) | 2018-03-30 | 2019-03-29 | Inhibiteur d'assemblage de protéines capsidiques contenant un cycle à cinq chaînons n-hétérocyclique, composition pharmaceutique et utilisation associées |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3778569A1 EP3778569A1 (fr) | 2021-02-17 |
| EP3778569A4 true EP3778569A4 (fr) | 2021-12-29 |
Family
ID=68058571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP19777163.7A Pending EP3778569A4 (fr) | 2018-03-30 | 2019-03-29 | Inhibiteur d'assemblage de protéines capsidiques contenant un cycle à cinq chaînons n-hétérocyclique, composition pharmaceutique et utilisation associées |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11597716B2 (fr) |
| EP (1) | EP3778569A4 (fr) |
| JP (1) | JP7434166B2 (fr) |
| KR (1) | KR20200136994A (fr) |
| CN (3) | CN115974753A (fr) |
| AU (2) | AU2019241321B2 (fr) |
| CA (1) | CA3094022A1 (fr) |
| PH (1) | PH12020551616A1 (fr) |
| SG (1) | SG11202009150RA (fr) |
| WO (1) | WO2019185016A1 (fr) |
| ZA (1) | ZA202006378B (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3154989B1 (fr) | 2014-06-11 | 2021-03-24 | Venatorx Pharmaceuticals, Inc. | Inhibiteurs de bêta-lactamases |
| WO2018218190A1 (fr) | 2017-05-26 | 2018-11-29 | VenatoRx Pharmaceuticals, Inc. | Inhibiteurs de protéines de liaison à la pénicilline |
| WO2018218154A1 (fr) | 2017-05-26 | 2018-11-29 | VenatoRx Pharmaceuticals, Inc. | Inhibiteurs protéiques de liaison à la pénicilline |
| WO2019118358A1 (fr) | 2017-12-11 | 2019-06-20 | VenatoRx Pharmaceuticals, Inc. | Modulateurs de l'assemblage de la capside de l'hépatite b |
| CN115974753A (zh) | 2018-03-30 | 2023-04-18 | 正大天晴药业集团股份有限公司 | 含有n杂五元环化合物和用途 |
| EP3805223A4 (fr) | 2018-05-25 | 2021-12-22 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Dérivé de 2,3-dihydro-1h-pyrrolizine-7-formamide et son application |
| JP2021527638A (ja) | 2018-06-11 | 2021-10-14 | ベナトルクス ファーマシューティカルズ，インク． | Ｂ型肝炎カプシドアセンブリモジュレーター |
| MX2021003150A (es) * | 2018-10-05 | 2021-07-06 | Univ Emory | Agentes monomericos y multimericos contra el vhb. |
| EA202092159A1 (ru) | 2019-01-25 | 2020-12-15 | Чиа Тай Тянцин Фармасьютикал Груп Ко., Лтд. | Содержащий n-гетероциклическое пятичленное кольцо ингибитор сборки капсидного белка, его фармацевтическая композиция и их применение |
| CN113365999B (zh) * | 2019-01-31 | 2023-04-14 | 正大天晴药业集团股份有限公司 | 含有吡咯并杂环的衣壳蛋白装配抑制剂 |
| WO2020205934A1 (fr) | 2019-04-03 | 2020-10-08 | Aligos Therapeutics, Inc. | Composés de pyrrole |
| WO2021058001A1 (fr) * | 2019-09-29 | 2021-04-01 | 正大天晴药业集团股份有限公司 | Forme cristalline de composé à hétérocycle azoté à cinq chaînons et son application |
| WO2021058002A1 (fr) * | 2019-09-29 | 2021-04-01 | 正大天晴药业集团股份有限公司 | Forme cristalline d'un inhibiteur de l'assemblage de la protéine de capside comportant un cycle à cinq chaînons avec n comme hétéroatome, et son application |
| WO2021093172A1 (fr) | 2019-11-13 | 2021-05-20 | 西安新通药物研究有限公司 | Inhibiteur du vhb et son utilisation |
| US20230107941A1 (en) * | 2019-12-10 | 2023-04-06 | VenatoRx Pharmaceuticals, Inc. | Hepatitis b capsid assembly modulators |
| CN113493441B (zh) * | 2020-04-03 | 2024-07-09 | 广东东阳光药业股份有限公司 | 新型螺环类化合物及其在药物中的应用 |
| EP4413984A1 (fr) | 2021-10-08 | 2024-08-14 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Combinaison pharmaceutique contenant un inhibiteur de protéine capsidique et un inhibiteur de la transcriptase inverse |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019241292A1 (fr) * | 2018-06-11 | 2019-12-19 | VenatoRx Pharmaceuticals, Inc. | Modulateurs d'assemblage de capside de l'hépatite b |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE041596T2 (hu) | 2004-07-30 | 2019-05-28 | Exelixis Inc | Pirrol származékok mint gyógyászati szerek |
| JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
| EP3357906B1 (fr) * | 2013-07-25 | 2019-12-04 | Janssen Sciences Ireland Unlimited Company | Dérivés de pyrrolamide substitués de glyoxamide et leur utilisation comme médicaments pour le traitement de l'hépatite b |
| US9567299B2 (en) | 2013-10-23 | 2017-02-14 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| DK3102572T3 (en) | 2014-02-06 | 2019-02-04 | Janssen Sciences Ireland Uc | SULFAMOYLPYRROLAMIDE DERIVATIVES AND THEIR USE AS MEDICINES TO TREAT HEPATITIS B |
| BR112018068177B1 (pt) * | 2016-03-09 | 2024-02-27 | Emory University | Composto, uso do composto e composição para eliminação do vírus da hepatite b com agentes antivirais |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| WO2018050110A1 (fr) | 2016-09-18 | 2018-03-22 | 正大天晴药业集团股份有限公司 | Nouvel inhibiteur d'assemblage de protéine capsidique |
| CN107721895B (zh) | 2017-10-13 | 2020-03-20 | 天津科技大学 | 新型五取代2,3-二氢吡咯衍生物及其制备方法和应用 |
| WO2019154343A1 (fr) | 2018-02-09 | 2019-08-15 | 正大天晴药业集团股份有限公司 | Inhibiteur d'assemblage de protéine capsidique, composition pharmaceutique et utilisation associée |
| CN111788204B (zh) | 2018-02-26 | 2023-05-05 | 吉利德科学公司 | 作为hbv复制抑制剂的取代吡咯嗪化合物 |
| CN115974753A (zh) | 2018-03-30 | 2023-04-18 | 正大天晴药业集团股份有限公司 | 含有n杂五元环化合物和用途 |
| EP3805223A4 (fr) | 2018-05-25 | 2021-12-22 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Dérivé de 2,3-dihydro-1h-pyrrolizine-7-formamide et son application |
| EA202092159A1 (ru) | 2019-01-25 | 2020-12-15 | Чиа Тай Тянцин Фармасьютикал Груп Ко., Лтд. | Содержащий n-гетероциклическое пятичленное кольцо ингибитор сборки капсидного белка, его фармацевтическая композиция и их применение |
| CN113365999B (zh) | 2019-01-31 | 2023-04-14 | 正大天晴药业集团股份有限公司 | 含有吡咯并杂环的衣壳蛋白装配抑制剂 |
| WO2021058002A1 (fr) | 2019-09-29 | 2021-04-01 | 正大天晴药业集团股份有限公司 | Forme cristalline d'un inhibiteur de l'assemblage de la protéine de capside comportant un cycle à cinq chaînons avec n comme hétéroatome, et son application |
| WO2021058001A1 (fr) | 2019-09-29 | 2021-04-01 | 正大天晴药业集团股份有限公司 | Forme cristalline de composé à hétérocycle azoté à cinq chaînons et son application |
-
2019
- 2019-03-29 CN CN202211543931.7A patent/CN115974753A/zh active Pending
- 2019-03-29 SG SG11202009150RA patent/SG11202009150RA/en unknown
- 2019-03-29 CN CN201980021317.4A patent/CN111868026B/zh active Active
- 2019-03-29 JP JP2020552331A patent/JP7434166B2/ja active Active
- 2019-03-29 CA CA3094022A patent/CA3094022A1/fr active Pending
- 2019-03-29 US US17/043,593 patent/US11597716B2/en active Active
- 2019-03-29 EP EP19777163.7A patent/EP3778569A4/fr active Pending
- 2019-03-29 CN CN202211627236.9A patent/CN115974754A/zh active Pending
- 2019-03-29 AU AU2019241321A patent/AU2019241321B2/en active Active
- 2019-03-29 KR KR1020207031226A patent/KR20200136994A/ko active Pending
- 2019-03-29 WO PCT/CN2019/080412 patent/WO2019185016A1/fr active Application Filing
-
2020
- 2020-09-29 PH PH12020551616A patent/PH12020551616A1/en unknown
- 2020-10-14 ZA ZA2020/06378A patent/ZA202006378B/en unknown
-
2023
- 2023-02-06 US US18/106,103 patent/US12116356B2/en active Active
- 2023-07-07 AU AU2023204386A patent/AU2023204386B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019241292A1 (fr) * | 2018-06-11 | 2019-12-19 | VenatoRx Pharmaceuticals, Inc. | Modulateurs d'assemblage de capside de l'hépatite b |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019241321A1 (en) | 2020-10-08 |
| US11597716B2 (en) | 2023-03-07 |
| EP3778569A1 (fr) | 2021-02-17 |
| JP2021519325A (ja) | 2021-08-10 |
| PH12020551616A1 (en) | 2021-08-16 |
| JP7434166B2 (ja) | 2024-02-20 |
| CN111868026B (zh) | 2022-11-25 |
| WO2019185016A1 (fr) | 2019-10-03 |
| US12116356B2 (en) | 2024-10-15 |
| AU2019241321B2 (en) | 2023-04-13 |
| KR20200136994A (ko) | 2020-12-08 |
| CN115974754A (zh) | 2023-04-18 |
| US20210017154A1 (en) | 2021-01-21 |
| CN111868026A (zh) | 2020-10-30 |
| SG11202009150RA (en) | 2020-10-29 |
| AU2023204386B2 (en) | 2024-11-21 |
| ZA202006378B (en) | 2024-02-28 |
| CA3094022A1 (fr) | 2019-10-03 |
| CN115974753A (zh) | 2023-04-18 |
| US20230183208A1 (en) | 2023-06-15 |
| AU2023204386A1 (en) | 2023-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3778569A4 (fr) | Inhibiteur d'assemblage de protéines capsidiques contenant un cycle à cinq chaînons n-hétérocyclique, composition pharmaceutique et utilisation associées | |
| EP3805264A4 (fr) | Anticorps anti-interleukine 17a, composition pharmaceutique et utilisation associées | |
| EP3741374A4 (fr) | Inhibiteur de mtor, composition pharmaceutique et son utilisation | |
| EP3915972A4 (fr) | Inhibiteur de l'ensemble de la capside contenant un anneau n-hétérocyclique à 5 éléments | |
| EP3917526A4 (fr) | Composés et leurs utilisations | |
| EP3706741A4 (fr) | Composition pharmaceutique et utilisation associée | |
| EP3753943A4 (fr) | Composé hétérocyclique, son application et composition pharmaceutique le comprenant | |
| EP3917934A4 (fr) | Composés et leurs utilisations | |
| EP3917517A4 (fr) | Composés et leurs utilisations | |
| EP3917529A4 (fr) | Composés et leurs utilisations | |
| EP3412669A4 (fr) | Composé tricyclique pour inhibiteur de protéine contenant un bromodomaine et préparation, composition pharmaceutique et son utilisation | |
| EP3941908A4 (fr) | Composés et leurs utilisations | |
| EP3805234A4 (fr) | Composé hétérocyclique aromatique, composition pharmaceutique et utilisation associées | |
| EP4037670A4 (fr) | Dérivés de 5-fluoronicotinamide et leurs utilisations | |
| EP3770148A4 (fr) | Inhibiteur de récepteur, composition pharmaceutique le comprenant et son utilisation | |
| EP4034535A4 (fr) | Composés d'aza-quinoléine et leurs utilisations | |
| EP3964512A4 (fr) | INHIBITEUR DE CASÉINE KINASE 1epsilon, COMPOSITION PHARMACEUTIQUE ET UTILISATION ASSOCIÉE | |
| EP3892621A4 (fr) | Composés d'halogénoallylamine et leur utilisation | |
| EP3952876A4 (fr) | Composés hétérocycliques et leurs utilisations | |
| EP3697411A4 (fr) | Nouvelle composition pharmaceutique et son utilisation | |
| EP3952875A4 (fr) | Composés hétérocycliques et leurs utilisations | |
| EP3952877A4 (fr) | Composés hétérocycliques et leurs utilisations | |
| EP3848049A4 (fr) | Composition pharmaceutique d'anticorps anti-tim3 et son utilisation | |
| EP3914593A4 (fr) | Composés et leurs utilisations | |
| EP3849992A4 (fr) | Inhibiteurs de cd73 et utilisations pharmaceutiques associées |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20201012 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20211125 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 409/12 20060101ALI20211119BHEP Ipc: A61P 31/20 20060101ALI20211119BHEP Ipc: A61K 31/4025 20060101ALI20211119BHEP Ipc: C07D 405/12 20060101ALI20211119BHEP Ipc: C07D 207/34 20060101AFI20211119BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20250217 |